Stefan Engelhardt

Professor, Founder and CSO at RNATICS GmbH

Presenter

Stefan Engelhardt, MD, PhD, is founder and Chief Scientific Officer of RNATICS GmbH, a spin-off of the Technical University of Munich (TUM) developing macrophage-targeted RNA therapeutics for fibrotic lung disease, whose lead candidate RCS-21 is currently undergoing Phase 1 clinical testing. He holds the Chair of Pharmacology and Toxicology at TUM and directs its Institute of Pharmacology and Toxicology. His research addresses non-coding RNAs in cardiovascular and pulmonary disease and their translation into targeted therapies. He is speaker of the Cluster of Excellence NUCLEATE, the Cluster for Nucleic Acid Therapeutics Munich (CNATM) and the DFG Collaborative Research Centre TRR 267. He studied medicine in Regensburg, Munich and at Harvard. He is a member of the German National Academy of Sciences Leopoldina and received TUM's Heinz Maier-Leibnitz Medal in 2025.